Want to see NBP full AI Analyst Report?
NBP Stock Chart & Stats
$1.79
$0.05(2.94%)
At close: 4:00 PM EDT
$1.79
$0.05(2.94%)
Day’s Range― - ―
52-Week Range$1.31 - $6.79
Previous Close$1.79
Volume178.26K
Average Volume (3M)493.25K
Market Cap
$157.18M
Enterprise Value$39.26M
Total Cash (Recent Filing)$190.85M
Total Debt (Recent Filing)$4.46M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding115,381,690
10 Day Avg. Volume1,025,875
30 Day Avg. Volume493,254
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$9.00Price Target Upside402.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Debt-free Balance SheetA sizable cash position combined with no debt gives NovaBridge meaningful flexibility to fund clinical development and absorb near-term operating losses. Management expects this runway to support multiple catalysts through a potential 2028 Phase III interim readout, reducing immediate solvency pressure.
Givastomig Clinical And Regulatory MomentumFast Track status, constructive FDA feedback, and encouraging mid-stage efficacy support advancement toward registrational development in a defined gastroesophageal cancer population. These milestones can improve partnering credibility and create a clearer path to future value if later trials confirm the results.
Diversified Pipeline With Advancing VIS-101The ophthalmology program adds a second clinical value driver beyond oncology, broadening NovaBridge’s potential development portfolio. Positive Phase IIa findings and planned advancement toward Phase IIb and Phase III create additional opportunities for future partnerships, milestones, and commercial outcomes.
Bears Say
Persistent Losses, Minimal Revenue, And Cash BurnNovaBridge has not established a stable revenue base or sustainable profitability, while recurring negative operating and free cash flow require continued balance-sheet support. Even with a smaller 2025 loss, prolonged cash burn can constrain investment capacity and increase dependence on future financing.
Phase III Execution Depends On Additional FinancingThe timing of the most important registrational step is not fully under management’s control because additional financing remains necessary. Delayed funding could push back pivotal development, extend the period without product revenue, and increase the likelihood of capital raising on unfavorable terms.
Crowded CLDN18.2 Market And Unresolved Patient StrategyA crowded CLDN18.2 field raises the bar for differentiation, clinical adoption, and future partnering interest. Uncertainty around the PD-L1-negative subgroup further narrows the currently articulated regulatory opportunity and could complicate trial design, positioning, and eventual market access.
NovaBridge Biosciences News
NBP FAQ
What was NovaBridge Biosciences’s price range in the past 12 months?
NovaBridge Biosciences lowest stock price was $1.31 and its highest was $6.79 in the past 12 months.
What is NovaBridge Biosciences’s market cap?
NovaBridge Biosciences’s market cap is $157.18M.
When is NovaBridge Biosciences’s upcoming earnings report date?
NovaBridge Biosciences’s upcoming earnings report date is Mar 31, 2027 which is in 176 days.
How were NovaBridge Biosciences’s earnings last quarter?
NovaBridge Biosciences released its earnings results on Aug 20, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.04.
Is NovaBridge Biosciences overvalued?
According to Wall Street analysts NovaBridge Biosciences’s price is currently Undervalued.
Does NovaBridge Biosciences pay dividends?
NovaBridge Biosciences does not currently pay dividends.
What is NovaBridge Biosciences’s EPS estimate?
NovaBridge Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NovaBridge Biosciences have?
NovaBridge Biosciences has 115,381,690 shares outstanding.
What happened to NovaBridge Biosciences’s price movement after its last earnings report?
NovaBridge Biosciences reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -3.535%.
Which hedge fund is a major shareholder of NovaBridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (402.79% Upside)
$9.00 (402.79% Upside)
Blogger Sentiment
Neutral
NBP Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 350.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $86.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Learn more about TipRanks Smart Score
Company Description
NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
NBP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong clinical and regulatory progress—most notably for givastomig (Fast Track designation, FDA Type B guidance, robust Phase Ib signals) and positive topline VIS-101 Phase IIa results—backed by a solid cash position and a debt-free balance sheet with runway through a 2028 Phase III interim readout. However, key execution risks remain: Phase III initiation is contingent on additional financing, the CLDN18.2 competitive landscape is intensifying, PD-L1 negative population strategy is unresolved, and the Visara ophthalmology path will likely require significant capital (and may dilute shareholders). Overall, the positives (clear clinical momentum, regulatory endorsements, and a healthy balance sheet) outweigh the operational and financing uncertainties, yielding cautious optimism but with notable execution risks.View all NBP earnings summariesNBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(402.79% Upside)
Technical Analysis
Ownership Overview
0.86% Insiders
0.07% Mutual Funds
13.22% Other Institutional Investors
84.67% Public Companies and
Individual Investors